Month: November 2022

Chike Mocha Mint Protein Iced Coffee is back!

ABILENE, Texas – November 9, 2022 – (Newswire.com)

Many say it’s ‘the most wonderful time of the year’ and Chike Nutrition customers would have to agree. Chike Nutrition is ringing in the holidays and bringing cheer with the return of their most popular and requested seasonal flavor, Chike Mocha Mint Protein Iced Coffee. Although Chike Mocha Mint Protein Iced Coffee is available online starting Nov. 8 and in over 500 locations nationwide, it is sure to sell out quickly.

This flavor is refreshing, balanced and has a true chocolate mint flavor reminding you of that cookie in a silver sleeve. The smell of smooth mint hits first, followed by sweet chocolate notes with mint to balance, and a mid-level sweetness finish. Better yet, each serving is packed with 20 grams of non-GMO whey protein, 150mg of caffeine, and only 1 gram of sugar and 110 calories. A truly healthy option that doesn’t compromise on taste.

A verified purchaser from last year named Heidi left a 5-star review stating, “This is the best flavor I’ve ever had. I need to stock up on 10 more bags since it’s a limited edition flavor!!! I love it!!!!” Clearly, Chike Nutrition’s customers are obsessed with Chike Mocha Mint Protein Iced Coffee.

Chike Mocha Mint Protein Iced Coffee takes the place of your sugary drive-thru coffee and is the ideal breakfast booster, healthy snack, or afternoon pick me-up. If you’re looking for extra holiday cheer, adding Chike Mocha Mint protein coffee powder into recipes easily enhances delicious treats, making them a healthier choice.

“There’s an extra layer of excitement from our customers this holiday season because of the return of our Chike Mocha Mint Protein Iced Coffee. We launched this seasonal flavor for the first time last year and we couldn’t keep up with the demand. Since then, our customers have constantly made requests for it to be a permanent flavor, so much so that we made extra this year! Don’t let an iced coffee drink during the cold weather keep you from trying Chike Mocha Mint Protein Iced Coffee. Grab a bag (or two) while you can and see what all of the hype is about. You won’t be disappointed!”, said Mac Mascorro, Brand Manager of Chike Nutrition.

It’s time to put on your mittens and try this seasonal Protein Iced Coffee that is sure to bring you cheer!

###

About Chike Nutrition

Chike Nutrition is based in Abilene, Texas and proudly manufactures and produces all nine (and counting!) of their current flavors, ensuring the quality and consistency that Chike Nutrition demands in their products. You can find all of the flavors on Chike Nutrition’s website and can follow new recipes, flavor launches, and more on Instagram and Pinterest.  Learn more about Chike in their overview video.

Contact Information:

Mac Mascorro

Brand Manager

mac@ilikechike.com

Press Release Service
by
Newswire.com

Original Source:

Chike Nutrition is Adding to ‘The Most Wonderful Time of the Year’

Accomplished technology executive and innovator Dr. Niko Pagoulatos joins Spectral MD

Niko Pagoulatos
DALLAS – …

SecurePortIV In Use SecurePortIV Catheter Securement Adhesive being applied for IV securement and site protection.
MINNEAPOLIS – November 8, 2022…

SAN DIEGO – November 8, 2022 – (Newswire.com)

Reach Healthcare is …

NEW YORK – November 8, 2022 – (Newswire.com)

AMC Health is pleased to announce the appointment of Mr. Steve Tsamaras, a seasoned financial executive, to the position of Chief Financial Officer. This strategic appointment will strengthen AMC Health’s executive team and follows the announcement made on 19 Oct. 2022 of AMC Health’s collaboration with global leader GE Healthcare. 

Mr. Tsamaras brings over 20 years of public and private company experience in a wide range of finance and business functions within various industries. He has a proven track record of, and accountability for, financial control and reporting, accounting, tax, M&A, risk and compliance, and audit, in his prior roles. He is a highly experienced finance leader having held a number of leadership roles and has helped companies maximize profitability, operational efficiencies, and capital market objectives.

“I am delighted that Steve is joining AMC Health and bringing with him his extensive financial services knowledge and experience and a proven track record of leading high-performing businesses,” said Nesim Bildirici, Chief Executive Officer of AMC Health. 

Prior to joining AMC Health, Mr. Tsamaras was Chief Accounting Officer for BVI Medical, a private medical device company. Steve has held divisional finance roles with General Electric, Siemens and Liberty Mutual. Steve is an alumnus of KPMG and PricewaterhouseCoopers. He obtained his C.P.A. license in the state of Massachusetts and holds a BS in accountancy from Bentley University.  

“I am very excited to be joining AMC Health at this important time in its history and look forward to working with Nesim Bildirici and the executive team in their objective of executing the delivery of the growth strategy.”

About AMC Health: 

Founded in 2002, AMC Health’s Virtual Care and Remote Patient Monitoring suite of solutions leverages a superior analytics platform and a simple user interface that integrates easily into clinical workflows. AMC Health’s advanced, real-time, analytics-driven, virtual care solutions have driven outstanding and measurable outcomes to hundreds of thousands of patients across the healthcare continuum, including payers, provider systems and governmental agencies. Its FDA Class II 510(k)-cleared, clinical decision support platform is combined with end-to-end, clinical and support RPM services that enable healthcare organizations to confidently extend their services beyond the four walls of hospital and ambulatory clinic settings. AMC Health’s unparalleled corpus of peer-reviewed, published studies highlight clinical improvements for conditions including heart failure, diabetes, and hypertension, resulting in reductions in hospital admissions and substantial financial returns on investment. For more information, visit www.amchealth.com.

Contact Information:

Mari Mescolotto

Chief Marketing Officer

mmescolotto@amchealth.com

561-245-0511

Press Release Service
by
Newswire.com

Original Source:

New Chief Financial Officer Hire Strengthens AMC Health’s Executive Leadership Team

WASHINGTON – November 8, 2022 – (Newswire.com)

A recently published article in Experimental Biology and Medicine (Volume 247, Issue 18, September, 2022) improves our understanding of genomic transposable elements and Parkinson’s disease. The study, led by Dr. Sulev Koks, head of Genetic Epidemiology Research at Perron Institute for Neurological and Translational Science and the Centre for Molecular Medicine and Innovative Therapeutics at Murdoch University (Australia), and Dr. John Quinn, chair of Neurobiology in the department of Pharmacology and Therapeutics at the University of Liverpool (United Kingdom), describes how transposable elements were associated with Parkinson’s subtypes and impact disease trajectory.

Transposable elements make up more than 70% of the human genome, but until recently, they have been considered as ‘junk’ DNA without any meaningful function. These elements have been largely ignored in most genetic studies and could therefore contribute to the currently unknown genetic factors that influence disease development. Prior studies by Koks and colleagues have shown that these elements have a significant regulatory role in the genome. They regulate the expression of many genes, orchestrate complex genetic activation where multiple genes are needed for a complex response, and a growing body of evidence suggests that these elements have a major pathogenetic effect, with several elements shown to cause disease.

This study, led by Dr. Koks, analyzed the variation of transposable elements and their impact on different trajectories of Parkinson’s disease. They used patient data from the Parkinson’s Progression Markers Initiative, and five-year follow-up data from Parkinson’s patients who also had whole genome sequencing data available. This allowed them to develop a comprehensive genomic screen for the transposable elements in these patients. Koks et al found that transposable elements were associated with Parkinson’s subtypes and disease trajectory. Some transposable elements predicted faster progression of the disease, with very fast deterioration of motor or cognitive functions. The effect of transposable elements wasn’t unidirectional. Depending on their type and position in the genome, these elements had a negative or positive effect. Some elements were associated with a strong and clinically meaningful change in functional Parkinson’s scores. At the same time, some transposable elements were protective and associated with a slower disease progression suggesting a slowing of neuronal loss and neurodegeneration.

Dr. Koks said: “Transposable elements are part of the genome which is known as the ‘dark genome.'” He continued: “Our study showed that the dark genome may have a much more significant impact on the pathophysiology of complex disease than previously estimated. The elements inside the dark genome could enhance or slow the progression of Parkinson’s disease and therefore open up new opportunities for precision medicine.” Dr. Quinn added, “Our body of work over a decade highlights the importance of targeting these elements for therapeutic intervention in the progression of neurodegenerative diseases which is the subject of our current work not only in Parkinson’s Disease but also Motor Neurone Disease. This could include repositioning of drugs from other disease areas in which these elements are implicated in disease progression.”

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said “This fascinating study by Koks and his colleagues demonstrates that the presence or absence of transposable elements controls the progressions trajectory of Parkinson’s Disease. It further underscores the importance of rigorous analysis of these genomic elements is essential for considering therapeutic opportunities.”

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership visit www.sebm.org. If you are interested in publishing in the journal, please visit http://ebm.sagepub.com.

For more information, please contact ebm@sebm.org.

Contact Information:

Benjamin Zimmer

bzimmer@sebm.org

Press Release Service
by
Newswire.com

Original Source:

Genomic transposable elements modify the progression of Parkinson’s disease

SAN DIEGO – November 8, 2022 – (Newswire.com)

AnaBios today announced th…